Found 408 clinical trials
Itacitinib in Advanced Hepatocellular Carcinoma (JAKaL)
protein inhibitor of the tyrosine kinase, JAK1, which is believed to enable cancer cells to metastasise to other parts of the body.
- 0 views
- 21 Jul, 2022
- 1 location
HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure
The efficacy and safety of HAIC combined with tyrosine kinase inhibitor and immunotherapy have been proved by the clinical research. In this single-arm, open-label, prospective study, for those
- 0 views
- 03 Dec, 2021
- 1 location
Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)
the inhibitor crizotinib. Crizotinib, which is a tyrosine kinase inhibitor (TKI), has been shown to be effective in tumors in several retrospective studies. Recently the FDA approved
- 0 views
- 07 Jun, 2021
- 39 locations
CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC
resistance to their tyrosine kinase inhibitors (TKIs), this study will look at how effective tepotinib is in combination with TKIs. This study will also measure a number of other things including safety of
- 0 views
- 10 Jul, 2022
- 1 location
Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease. (ILLUMINATE)
) following progression on EGFR Tyrosine Kinase Inhibitors.. Study population: Individuals may be eligible to enrol in this trial if aged 18 or over and have been diagnosed with advanced non
- 27 views
- 10 Feb, 2022
- 12 locations
Evaluation of PKU Express Plus
: adherence to prescribed dietary intakes, palatability, usability, gastrointestinal tolerance, neophobia score, blood phenylalanine and tyrosine levels, timeframe to transition and contribution of PKU
- 0 views
- 07 Oct, 2021
- 3 locations
The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RA
disability. Tofacitinib(TF) is a new type of oral tyrosine kinase inhibitor (JAKi) for the treatment of moderate to severe active RA. However, there is alack of Chinese data on the joint scheme, long-term
- 0 views
- 26 Jun, 2021
- 1 location
The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer
and antiestrogen therapies could be an appropriate therapeutic modality. Anlotinib is a novel multi-target tyrosine kinase inhibitor that effectively inhibit VEGFR, FGFR, PDGFR, c-KIT, c-MET and RET
- 0 views
- 21 Oct, 2021
- 1 location
Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer (ORAKLE)
Crizotinib is a first-generation ALK tyrosine kinase inhibitor (ITK-ALK). It is the standard first-line treatment for patients with advanced NSCLC with ALK gene rearrangement. Alectinib
- 0 views
- 29 Apr, 2022
- 30 locations
Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC (FL-ALTER)
experience significantly varying duration of response and survival rate. Anlotinib is an efficient multi-target tyrosine kinase inhibitor (TKI) that effectively block the migration and proliferation of
- 1 views
- 17 Feb, 2022